Olmesartan | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Olmesartan
HEALTH CANADA PATENTS

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Olmesartan

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

109 API Suppliers, 44 USDMF, 40 CEP/COS, 18 JDMF, 31 EU WC, 40 KDMF, 24 NDC API, 58 Listed Suppliers, $ API Reference Price

109 API Suppliers
44 USDMF
40 CEP/COS
18 JDMF
31 EU WC
40 KDMF
24 NDC API
58 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

46 Intermediates Suppliers

46 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

900 FDF Dossiers, 194 FDA Orange Book, 454 Europe, 51 Canada, 36 Australia, 165 Listed Dossiers

900 FDF Dossiers
194 FDA Orange Book
454 Europe
51 Canada
36 Australia
165 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 20MG, TABLET;ORAL - 40MG, TABLET;ORAL - 5MG, TABLET;ORAL - 12.5MG;20MG, TABLET;ORAL - 12.5MG;40MG, TABLET;ORAL - 25MG;40MG, TABLET;ORAL - EQ 10MG BASE;20MG, TABLET;ORAL - EQ 10MG BASE;40MG, TABLET;ORAL - EQ 5MG BASE;20MG, TABLET;ORAL - EQ 5MG BASE;40MG

TABLET;ORAL - 20MG
TABLET;ORAL - 40MG
TABLET;ORAL - 5MG
TABLET;ORAL - 12.5MG;20MG
TABLET;ORAL - 12.5MG;40MG
TABLET;ORAL - 25MG;40MG
TABLET;ORAL - EQ 10MG BASE;20MG
TABLET;ORAL - EQ 10MG BASE;40MG
TABLET;ORAL - EQ 5MG BASE;20MG
TABLET;ORAL - EQ 5MG BASE;40MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 4 SPI Pharma, 2 Seqens, 12 DKSH, 5 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 12 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 21 BASF, 3 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 38 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 21 Roquette, 9 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 12 Sigachi Industries, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

78 Fillers, Diluents & Binders, 56 Coating Systems & Additives, 33 Direct Compression, 32 Disintegrants & Superdisintegrants, 31 Controlled & Modified Release, 27 Thickeners and Stabilizers, 26 Lubricants & Glidants, 23 Granulation, 18 Topical, 17 Co-Processed Excipients, 16 Film Formers & Plasticizers, 16 Solubilizers, 10 Parenteral, 9 Taste Masking, 8 Emulsifying Agents, 7 Rheology Modifiers, 6 Chewable & Orodispersible Aids, 6 API Stability Enhancers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

78 Fillers, Diluents & Binders
56 Coating Systems & Additives
33 Direct Compression
32 Disintegrants & Superdisintegrants
31 Controlled & Modified Release
27 Thickeners and Stabilizers
26 Lubricants & Glidants
23 Granulation
18 Topical
17 Co-Processed Excipients
16 Film Formers & Plasticizers
16 Solubilizers
10 Parenteral
9 Taste Masking
8 Emulsifying Agents
7 Rheology Modifiers
6 Chewable & Orodispersible Aids
6 API Stability Enhancers
5 Empty Capsules
5 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 91 NEWS #PharmaBuzz

3 DATA COMPILATION #PharmaFlow
91 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 440 Finished Drug Prices, 14 Annual Reports

1 US Medicaid Prescriptions
440 Finished Drug Prices
14 Annual Reports

MARKET PLACE

31 APIs, 7 FDF Dossiers, 1 Intermediates

31 APIs
7 FDF Dossiers
1 Intermediates

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 2 USP, 4 JP, 13 Others

2 EDQM
2 USP
4 JP
13 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 811 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 3Merck Canada Inc.

filter Patent Reset all filters

3 All

01 32061607

filter Product Reset all filters

3 All

01 3Olmesartan Medoxomil

filter Dosage Reset all filters

3 All

01 3Tablet

filter Exp Date Reset all filters

3 All

01 32012-02-20

Product Main Page

01

Merck Canada Inc.

Olmesartan Medoxomil

Antibody Engineering

Not Confirmed

Merck Canada Inc.

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1991-01-19

Olmesartan Medoxomil

Brand Name : OLMETEC

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1991-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Merck Canada Inc.

Olmesartan Medoxomil

Antibody Engineering

Not Confirmed

Merck Canada Inc.

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan Medoxomil

Brand Name : OLMETEC

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 20 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Merck Canada Inc.

Olmesartan Medoxomil

Antibody Engineering

Not Confirmed

Merck Canada Inc.

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Olmesartan Medoxomil

Brand Name : OLMETEC

Patent Number : 2061607

Filing Date : 1992-02-20

Strength per Unit : 40 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2012-02-20

Date Granted : 1999-01-19

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?